Key facts
- This page summarizes David Dornan's Form 4 filing for Elevation Oncology, Inc. (ELEV).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 20 Feb 2024, 16:52.
David Dornan - 15 Feb 2024 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)
- Reporting relationship
- CHIEF SCIENTIFIC OFFICER
- Issuer ticker
- ELEV
- Reported as of
- 15 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Feb 2024, 16:52:31 UTC
- Prior SEC filing
- 17 Feb 2023
- Next SEC filing
- 19 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Yang, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Dornan filed Form 4 for Elevation Oncology, Inc. (ELEV) on 20 Feb 2024.
Change
- Previous filing in this sequence was filed on 17 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELEV
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +225,000
- Change %
- Price
- $0.000000
- Shares after
- 225,000
- Date
- 15 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 225,000
- Exercise price
- $2.77
- Footnotes
- F1
ELEV
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +37,500
- Change %
- Price
- $0.000000
- Shares after
- 37,500
- Date
- 15 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,500
- Exercise price
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The stock option vests as to 25% of the total shares on February 15, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Footnote F2
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
25% of the RSUs vest on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Footnote F4
The RSUs do not expire; they either vest or are canceled prior to the vesting date.